Antifungal efficacy of Myrtus communis essential oils on oral candidiasis in immunosupressed rats

Journal of Medicinal Plants

Volumn 10, Issue 38, 2011, Pages 102-116

  Najib Zadeh, T ^a   Yadegari, M H ^a   Naghdi Badi, H ^b   Salehnia, A ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c Khorraman Pharmaceutical Co   (Iran)

Author keywords

Candida albicans; Essential oil; Histopathological evaluations; Microbiological; Myrtus communis; Oral candidiasis

Indexed keywords

LIMONENE; LINALOOL; MYRTUS COMMUNIS EXTRACT; NYSTATIN; PINENE; PLACEBO; TERPINEOL;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG EFFICACY; GAS CHROMATOGRAPHY; IMMUNE DEFICIENCY; MASS FRAGMENTOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MYRTLE; NONHUMAN; RAT; THRUSH;

CANDIDA ALBICANS; MYRTUS COMMUNIS; RATTUS;

EID: 80053289571     PISSN: 2717204X     EISSN: 27172058     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 1995; 20 (1): 115-25.
2. Calderone RA and Fonzi WA. Virulence factors of Candida albicans. Trends in Microbiol. 2001; 9 (7): 327-35. (Pubitemid 32575277)
3. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis. 2001; 33: 1692-6. (Pubitemid 33044535)
4. Samaranayake LP. Oral mycoses in HIV infections. Oral Surg. Oral Med. Oral Pathol. 1992; 73: 171-80.
5. Dignani MC, Solomkin JS, Anaissie EJ. Candida. In: Anaissie EJ, McGinnis MR and Pfaller MA, eds. Clinical Mycology. Philadelphia: Churchill Livingstone, 2003, pp: 195-227.
6. Samaranayake LP and Lamey PJ. Oral Candidosis: 1. Clinicopathological aspects. Dental Update, 1988; 15: 227-31.
7. MacPhail LM, Greenspan D, Dodd CL, Heinic GS, Beck C and Ekoku E. Association of fungal species with oral candidiasis in HIV infection. J. Dent. Res. 1993; 72: 353.
8. Samaranayake YH and Samaranayake LP. Experimental oral candidiasis in animal models. Clin. Microbiol. Rev. 2001; 14 (2): 398-429. (Pubitemid 32294677)
9. Ellepola ANB and Samaranayake LP. Oral candidal infections and antimycotics. Crit. Rev. Oral Biol. Med. 2000; 11 (2): 172-98. (Pubitemid 30481379)
10. Kauffman CA and Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997; 53 (4): 539-49. (Pubitemid 27145951)
11. Ahmad S, Khan Z, Mustafa AS and Khan ZU. Seminested PCR for diagnosis of candidemia: Comparison with culture, antigen detection, and biochemical methods for species identification. J. Clin. Microbiol. 40: 2483-9.
12. Baghalian K and Naghdi Badi H. Volatile oil crops; their biology, biochemistry, and production. Andarz Publications. 2000, pp: 139-88.
13. Ghasemi Dehkordi N (Ed.). Iranian Herbal Pharmacopoeia (IHP). Ministry of Health Pub, Tehran. 2002, vol. 2, pp: 749-53.
14. Garg SC, Dengre SL. Antifungal activity of the essential oil of Myrtus Communis Var Microphylla. Herba Hungarica 1988; 27: 123-6.
15. Martinetz H, Johnson M, Phillips B. Antimicrobial effects of Myrtus communis L. essential oil on cilinical isolates of Fusarium and Penicilium. Med. Plant. 1998; 34 (6): 85-9.
16. Mccoy K, Lima J. Antimicrobial activity of Myrtus communis L. against Candida albicans. Med Hypo: 2003; 89 (15): 166-71.
17. Bonjar GHS, Nik AK, Aghighi S. Antibacterial and antifungal survey in plants used in indigenous herbal-medicine of south east regions of Iran. J. Biol. Sci. 2004; 4: 405-12.
18. Miller P, Danniel R. Inhibitory Effects of Zingiber officinalis and Myrtus Communis L. Against Dimatiaceouses. Fito. 2005; 22 (8): 211-5.
19. Ameziane N, Boubaker H, Boudyach H, Msanada F, Jilal A and Ait Benaoumar A. Antifungal activity of Moroccan plants against citrus fruit pathogens. Agron. Sustain. Dev. 2007; 27: 273-7. (Pubitemid 47443756)
20. Owlia P, Saderi H, Aghaee H, Yaraee R and Zayeri F. The effect of Myrtus communis L. essential oil on treatment of Herpes simplex infection in animal model. Iranian J. Medicinal and Aromatic Plants 2007; 23 (2): 157-65.
21. Romani A, Coinu R, Carta S, Pinelli P, Galardi C, Vincieri FF and Franconi F. Evaluation of antioxidant effect of different extracts of Myrtus communis L. Free Radic. Res. 2004; 38 (1): 97-103. (Pubitemid 38128520)
22. Feisst C, Franke L, Appendino G, Werz O. Identification of molecular targets of the oligomeric nonprenylated acylphloroglucinols from Myrtus communis and their implication as anti-inflammatory compounds. J. Pharmacol. Exp. Ther. 2005; 315(1): 389-96. (Pubitemid 41380535)
23. Mendes MM, Gazarini LC and Rodrigues ML. Acclimation of Myrtus communis to contrasting Mediterranean light environments: Effects on structure and chemical composition of foliage and plant water relations. Environ. Exp. Bot. 2001; 45: 165-78. (Pubitemid 32224554)
24. Azadbakht M, Ziaiye H, Abdollahi F and Shabankhani B. Effect of Methanolic essence and extract of Myrtus Communis on Trichomonas Vaginalis. Journal of Medical Faculty Guilan University of Medical Sci. 2004; 48 (12): 8-13.
25. Khalighi-Sigaroodi F, Jarvandi S and Taghizadeh M. Therapeutic indications of medicinal plants. Arjmand Pub. Tehran, Iran. 2010, pp: 181-4.
26. British Pharmacopoeia, HMSO, London, 1988, pp: 2, A137-A138.
27. Adams RP. Identification of essential oil components by gas chromatography/quadrupole mass spectroscopy. Allured Publishing. Carol Stream, IL, USA 2001, p: 469.
28. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa. 1997.
29. Chami N, Chami F, Bennis S, Trouillas J and Remmal A. Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats. Braz. J. Infect. Dis. 2004; 8 (3): 217-26.
30. Martinez A, Regardera J, Jimenez E, et al. Antifungal efficacy of GM237354,a sordarin derivative, in experimental oral oandidiasis in immunosuppressed rats. Antimicrob. Agents Chemother. 2001; 45: 1008-13. (Pubitemid 32230976)
31. Martinez A, Ferrer S, Santos I, Jimenez E, Sparrowe J, Regadera J, De Las Heras FG and Gargallo-Viola D. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats. Antimicrob. Agents Chemother. 2001; 45 (12): 3304-9.
32. Ahmet U, Tonay I, Mehiha UH and Hande D. Immune deficiency and cryptosporidiosis in rats. Turk. J. Vet. Anim. Sci. 2003; 27: 1187-92.
33. Najib-Zadeh T. Evaluation of Antifungal Efficacy of Satureja khuzestanika and Myrtus communis Essential Oils on Oral Candidiasis in Immunosupressed Rats (In Persian). M.Sc. Thesis. Tarbiat Modares University, Iran, 2009.
34. Carleton HM.Carleton's Histological tednique. Oxford University press 1980, pp: 520.
35. Mc Manus FA and Mowry RW. Staining methods. In: Hober PB, ed. Histology and Histochemistry. New York: Harper and Brothers; 1965.
36. Cohn HJ. Staining procedures used by the Biological stain Commission. New York, Biotech Publication 1994.
37. Smith A and Bruton J. A Colour atlas of histological Staining techniques. Wolfe Medical Publications, London, 1978, p: 192.
38. Davenport HA. Staining Sections. In: Davenport HA, editor. Histological and Histochemical Techniques. Philadelphia: W.B Saunders, 1960: 217-62.
39. Rasooli I, Moosavi ML, Rezaee MB and Jaimand K. Susceptibility of microorganisms to Myrtus communis L. essential oil and its chemical composition. J. Agric. Sci. Technol. 2002; 4: 127-33.
40. Russell C and Jones JH. Effects of oral inoculation of Candida albicans in tetracycline - treated rats. J. Med. Microbiol. 1973; 6: 275-79.
41. Fisker AV, Rindom Schiøtt C and Phillipsen HP. Short-term oral condidosis in rats, with special reference to the site of infection. Acta Pathol. Microbiol. Immunol. Scand B. 1982; 90 (1): 49-57. (Pubitemid 12170445)
42. Philipsen HP, Cleaton PJ, Fisker AV. Correlative light microscopic and scanning electron microscopic study of completely and incompletely orthokeratinized rat oral epithelium. European Journal of Oral Sci. 1982; 90: 255-262.
43. O'Grady J. Trauma and oral candidosis. M.D.Sc. thesis. University of Melbourne, Melbourne, Australia. 1986.
44. Kimura LH and Pearsall NN. Relationship between germination of Candida albicans and increased adherence to human buccal epithelial cells. Infect. Immun. 1980; 28: 464-8. (Pubitemid 10102083)
45. Martin MV, Craig GT and Lamb DJ. An investigation of the role of true hypha production in the pathogenesis of experimental oral candidosis. Sabouraudia 1984; 22 (6): 471-6. (Pubitemid 15186592)
46. Odds FC. Candida and candidiasis. Leicester University Press, Leicester, UK. 1979, pp: 382.
47. Seelig MS. Mechanisms by which antibiotics increase the incidence and severity of candidiasis and alter the immunological defenses. Bacteriol. Rev. 1966; 30: 442-59.
48. Knight L and Fletcher J. Growth of Candida albicans in saliva: Stimulation by glucose associated with antibiotics, corticosteroids and diabetes mellitus. J. Infect. Dis. 1971; 123 (4): 371-7.